Hugh K.
- Country
- Ireland
- Department
- Neurology
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- A Randomized, Double-Blind Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib Extension
Data & Insights
Has run more than one trial at 26 of 204 partner sites.
Specializations
Neurological Disorders
This investigator specializes in the study of multiple sclerosis, focusing on evaluating innovative therapeutic approaches for managing relapsing forms of the condition.
- Relapsing Multiple Sclerosis Management
- Novel Treatment Evaluation
- Disease Modification Strategies
Their research interests center on advancing treatment options for patients with relapsing multiple sclerosis through comparative therapeutic evaluations.
Therapeutic Innovation
The investigator examines therapeutic efficacy in neurological conditions, with particular attention to comparative assessment of emerging treatments.
- Treatment Comparison Studies
- Clinical Efficacy Assessment
- Safety Profile Analysis
Their work encompasses comprehensive evaluation of therapeutic interventions for neurological disorders.
Clinical Outcomes
Focus areas include investigating relapse frequency reduction and evaluating therapeutic responses in multiple sclerosis patients.
- Relapse Prevention
- Treatment Response Assessment
- Clinical Outcomes Measurement
The investigator's research emphasizes quantifiable improvements in patient outcomes through therapeutic intervention.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.